Dr. Fooke-Achterrath Laboratorien GmbH develops, manufactures and distributes in-vitro diagnostics nationally and internationally for detecting sensitizations to allergens and autoimmune diseases. The company is certified to DIN EN ISO 13485:2016 for development, manufacturing and distribution, and its microbiology department is accredited to DIN EN ISO/IEC 17025. Domestic sales are handled by an internal field force of five medical device advisors, while international sales are managed mainly through a distributor network overseen by a Business Development Manager. In fiscal 2024 the laboratories recorded revenue of T€ 9,511 with an average workforce of 62 employees and a net income of € 1,195,531.70.
Die Entwicklung, Produktion und der Vertrieb von immunologischen in-vitro Diagnostika.
Converted using the official Destatis and Eurostat correspondence tables; ISIC Rev. 4 is the United Nations' international industry classification.
This summary was generated with the help of AI. See our Data Quality Notice. Report error?
Source: German Commercial Register (Handelsregister) Neuss Local Court, HRB 5712 (as of 30 October 2026)
| Name | Type | City |
|---|---|---|
| Margrit Fooke-Achterrath | Geschäftsführer(in) | Neuss |
| Kristina Fooke-Clemens | Geschäftsführer(in) | Grevenbroich |
Source: German Commercial Register (Handelsregister) Neuss Local Court, HRB 5712 (as of 30 October 2026)
| Date | Event Type | Event |
|---|---|---|
| 13.12.2023 | Business Purpose Update | Die Entwicklung, Produktion und der Vertrieb von immunologischen in-vitro Diagnostika. |
| 24.11.2020 | Registered Seat Change | 16816 Neuruppin |
| 05.05.2011 | Business Address Change | Habichtweg 16, 41468 Neuss |
| Date | Type | Change | Total Capital |
|---|---|---|---|
| 13.12.2023 | Capital Decrease | -24.400 € | 25.600 € |
| 14.10.2002 | Share Capital Set | — | 50.000 DM |
Source: German Commercial Register (Handelsregister) Neuss Local Court, HRB 5712 (as of 30 October 2026)
| Year | Revenue | Profit | Balance | Employees |
|---|---|---|---|---|
| 2024 | Rohergebnis€8M2 | €1,206,001 | €12,431,339 | — |
| 2023 | Rohergebnis€8.6M2 | €1,666,592 | €11,984,227 | — |
| 2022 | Rohergebnis€8.2M2 | €1,451,239 | €11,073,270 | — |
| 2021 | Rohergebnis€7M2 | €1,031,579 | €10,054,025 | — |
| 2020 | Rohergebnis€6.2M2 | €485,625 | €9,139,681 | — |
| 2019 | Rohergebnis€6.6M2 | €415,468 | €8,492,821 | — |
| 2018 | Rohergebnis€6.4M2 | €172,955 | €7,894,223 | — |
| 2017 | ≤ €12M1 | €283,259 | €7,830,073 | — |
| 2016 | ≤ €12M1 | €335,093 | €7,944,848 | — |
| 2015 | ≤ €12M1 | €342,504 | €8,388,140 | — |
1 Small companies are not required to publish a profit-and-loss statement (§ 326 (1) HGB). The figure shown is the statutory ceiling under § 267 HGB where the balance-sheet total makes it binding — a company may exceed at most one of the three size criteria.
2 Rohergebnis nach § 276 HGB: Umsatzerlöse abzüglich Materialaufwand bzw. Herstellungskosten. Kleine und mittelgroße Kapitalgesellschaften dürfen diese Posten zusammenfassen; die Umsatzerlöse selbst sind dann nicht veröffentlicht und liegen über dem Rohergebnis.
Sign in to download data
Source: German Commercial Register (Handelsregister) Neuss Local Court, HRB 5712 (as of 30 October 2026)
| Cost type | Amount | Share |
|---|---|---|
| Personnel Costs | €4,244,680 | 93.4% |
| Depreciation | €292,365 | 6.4% |
| Interest & Similar | €7,500 | 0.2% |
